Fulcrum Therapeutics, Inc.
USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4
Last updated:
Abstract:
The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
Status:
Application
Type:
Utility
Filling date:
5 Oct 2018
Issue date:
22 Oct 2020